Pennsaid® (1.5% w/w diclofenac sodium solution) is a topical non-steroidal anti-inflammatory (NSAID) developed by Nuvo Research Inc. (TSE: NRI) for use as a treatment of osteoarthritis (OA) of the knee.
Based on Nuvo's skin-penetrating technology, Pennsaid® allows diclofenac to be delivered directly to the knee via topical application to the surface of the skin thereby minimizing systemic side effects that are usually associated with oral therapies. 
Nuvo Research has recently received an approvable letter from the USFDA for Pennsaid® (1.5% w/w diclofenac sodium solution).
According to Dr. Henrich Guntermann, Nuvo's President and CEO:
"This approvable letter is a great achievement for our Company and a step forward to the commercialization of Pennsaid in the U.S. We plan to work closely with the FDA to resolve these outstanding matters required to obtain final approval and expect to provide further information following our meeting with the FDA."
Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company with headquarters in Mississauga, Ontario and research and development facility in San Diego, California and manufacturing facilities in Varennes, Quebec and Wanzleben, Germany.
Source: Nuvo Research Inc. (a pdf file)
Comment Preview